These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
569 related articles for article (PubMed ID: 33921727)
1. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. Ligorio F; Fucà G; Zattarin E; Lobefaro R; Zambelli L; Leporati R; Rea C; Mariani G; Bianchi GV; Capri G; de Braud F; Vernieri C Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921727 [TBL] [Abstract][Full Text] [Related]
2. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862 [TBL] [Abstract][Full Text] [Related]
3. Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study. Hao L; Dong J; Yu H; Chen J; Han X; Pan Y Transl Cancer Res; 2023 Oct; 12(10):2726-2741. PubMed ID: 37969380 [TBL] [Abstract][Full Text] [Related]
4. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor. Chen X; Hong X; Chen G; Xue J; Huang J; Wang F; Ali WADS; Li J; Zhang L Transl Oncol; 2022 Mar; 17():101338. PubMed ID: 34999541 [TBL] [Abstract][Full Text] [Related]
5. The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis. Provenzano L; Lobefaro R; Ligorio F; Zattarin E; Zambelli L; Sposetti C; Presti D; Montelatici G; Ficchì A; Martinetti A; Arata A; Del Vecchio M; Lauria Pantano C; Formisano B; Bianchi GV; Capri G; de Braud F; Vernieri C; Fucà G Ther Adv Med Oncol; 2023; 15():17588359231165978. PubMed ID: 37063779 [TBL] [Abstract][Full Text] [Related]
6. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Şahin AB; Cubukcu E; Ocak B; Deligonul A; Oyucu Orhan S; Tolunay S; Gokgoz MS; Cetintas S; Yarbas G; Senol K; Goktug MR; Yanasma ZB; Hasanzade U; Evrensel T Sci Rep; 2021 Jul; 11(1):14662. PubMed ID: 34282214 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series. Bergin ART; Luen SJ; Savas P; Boolell V; Cho D; Lynch J; Nott L; Stuart-Harris R; Teo LN; Yap SY; Loi S Asia Pac J Clin Oncol; 2019 Dec; 15(6):377-382. PubMed ID: 31321873 [TBL] [Abstract][Full Text] [Related]
8. The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype. Tiainen S; Rilla K; Hämäläinen K; Oikari S; Auvinen P Breast Cancer Res Treat; 2021 Jan; 185(1):63-72. PubMed ID: 32948994 [TBL] [Abstract][Full Text] [Related]
9. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot XB; Burris HA; Petersen JA; De Haas S; Hoersch S; Patre M; Ellis PA Cancer; 2019 Nov; 125(22):3974-3984. PubMed ID: 31318460 [TBL] [Abstract][Full Text] [Related]
10. Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel. Hopkins AM; Rowland A; McKinnon RA; Sorich MJ Front Oncol; 2019; 9():789. PubMed ID: 31508358 [No Abstract] [Full Text] [Related]
11. A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. Gamucci T; Pizzuti L; Natoli C; Mentuccia L; Sperduti I; Barba M; Sergi D; Iezzi L; Maugeri-Saccà M; Vaccaro A; Magnolfi E; Gelibter A; Barchiesi G; Magri V; D'Onofrio L; Cassano A; Rossi E; Botticelli A; Moscetti L; Omarini C; Fabbri MA; Scinto AF; Corsi D; Carbognin L; Mazzotta M; Bria E; Foglietta J; Samaritani R; Garufi C; Mariani L; Barni S; Mirabelli R; Sarmiento R; Graziano V; Santini D; Marchetti P; Tonini G; Di Lauro L; Sanguineti G; Paoletti G; Tomao S; De Maria R; Veltri E; Paris I; Giotta F; Latorre A; Giordano A; Ciliberto G; Vici P Cancer Biol Ther; 2019; 20(2):192-200. PubMed ID: 30403909 [TBL] [Abstract][Full Text] [Related]
12. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L; Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691 [TBL] [Abstract][Full Text] [Related]
13. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717 [TBL] [Abstract][Full Text] [Related]
14. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab? Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M J BUON; 2015; 20(3):714-22. PubMed ID: 26214622 [TBL] [Abstract][Full Text] [Related]
15. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Pizzuti L; Krasniqi E; Sperduti I; Barba M; Gamucci T; Mauri M; Veltri EM; Meattini I; Berardi R; Di Lisa FS; Natoli C; Pistelli M; Iezzi L; Risi E; D'Ostilio N; Tomao S; Ficorella C; Cannita K; Riccardi F; Cassano A; Bria E; Fabbri MA; Mazzotta M; Barchiesi G; Botticelli A; D'Auria G; Ceribelli A; Michelotti A; Russo A; Salimbeni BT; Sarobba G; Giotta F; Paris I; Saltarelli R; Marinelli D; Corsi D; Capomolla EM; Sini V; Moscetti L; Mentuccia L; Tonini G; Raffaele M; Marchetti L; Minelli M; Ruggeri EM; Scavina P; Bacciu O; Salesi N; Livi L; Tinari N; Grassadonia A; Fedele Scinto A; Rossi R; Valerio MR; Landucci E; Stani S; Fratini B; Maugeri-Saccà M; De Tursi M; Maione A; Santini D; Orlandi A; Lorusso V; Cortesi E; Sanguineti G; Pinnarò P; Cappuzzo F; Landi L; Botti C; Tomao F; Cappelli S; Bon G; Pelle F; Cavicchi F; Fiorio E; Foglietta J; Scagnoli S; Marchetti P; Ciliberto G; Vici P Ther Adv Med Oncol; 2021; 13():17588359211059873. PubMed ID: 35173816 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine. Sahin TK; Akyildiz A; Dogan OT; Kavgaci G; Guven DC; Aksoy S Pharmaceuticals (Basel); 2024 Jun; 17(7):. PubMed ID: 39065675 [TBL] [Abstract][Full Text] [Related]
17. Association of immune inflammatory biomarkers with pathological complete response and clinical prognosis in young breast cancer patients undergoing neoadjuvant chemotherapy. Li F; Wang Y; Dou H; Chen X; Wang J; Xiao M Front Oncol; 2024; 14():1349021. PubMed ID: 38380360 [TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614 [TBL] [Abstract][Full Text] [Related]
19. Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. Ligorio F; Zambelli L; Bottiglieri A; Castagnoli L; Zattarin E; Lobefaro R; Ottini A; Vingiani A; Pupa SM; Bianchi GV; Capri G; Pruneri G; de Braud F; Vernieri C Ther Adv Med Oncol; 2021; 13():17588359211006960. PubMed ID: 33948122 [TBL] [Abstract][Full Text] [Related]
20. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. Baselga J; Cortés J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM J Clin Oncol; 2014 Nov; 32(33):3753-61. PubMed ID: 25332247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]